Updated International Consensus Guidelines on the Management of Cytomegalovirus in Solid-Organ Transplantation

被引：581

作者：

Kotton, Camille N. ^{[1
]}

Kumar, Deepali ^{[2
]}

Caliendo, Angela M. ^{[3
]}

Asberg, Anders ^{[4
]}

Chou, Sunwen ^{[5
]}

Danziger-Isakov, Lara ^{[6
]}

Humar, Atul ^{[7
]}

机构：

[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA 02114 USA

[2] Univ Alberta, Edmonton, AB, Canada

[3] Brown Univ, Alpert Med Sch Brown, Providence, RI 02912 USA

[4] Univ Oslo, Sch Pharm, Dept Pharmaceut Biosci, Oslo, Norway

[5] Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA

[6] Cincinnati Childrens Hosp Med Ctr, Div Infect Dis, Cincinnati, OH 45229 USA

[7] Univ Alberta, Dept Med, Alberta Transplant Inst, Edmonton, AB, Canada

来源：

TRANSPLANTATION | 2013年 / 96卷 / 04期

关键词：

Cytomegalovirus; CMV; Ganciclovir; Prevention; Prophylaxis; Resistance; Treatment; Valganciclovir; T-CELL RESPONSES; DRUG-RESISTANT CYTOMEGALOVIRUS; EPSTEIN-BARR-VIRUS; EXTENDED VALGANCICLOVIR PROPHYLAXIS; BRONCHIOLITIS OBLITERANS SYNDROME; BRONCHOALVEOLAR LAVAGE FLUID; HEPATIC-ARTERY THROMBOSIS; MANNOSE-BINDING LECTIN; VS. ORAL GANCICLOVIR; LONG-TERM RECIPIENT;

D O I：

10.1097/TP.0b013e31829df29d

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Cytomegalovirus (CMV) continues to be one of the most common infections after solid-organ transplantation, resulting in significant morbidity, graft loss, and adverse outcomes. Management of CMV varies considerably among transplant centers but has been become more standardized by publication of consensus guidelines by the Infectious Diseases Section of The Transplantation Society. An international panel of experts was reconvened in October 2012 to revise and expand evidence and expert opinion-based consensus guidelines on CMV management, including diagnostics, immunology, prevention, treatment, drug resistance, and pediatric issues. The following report summarizes the recommendations.

引用

页码：333 / 360

页数：28

共 272 条

[61] Intragraft Cytomegalovirus Protein Expression Is Associated With Reduced Renal Allograft Survival [J].

Dzabic, Mensur ;

Rahbar, Afsar ;

Yaiw, Koon-Chu ;

Naghibi, Mansour ;

Religa, Piotr ;

Fellstrom, Bengt ;

Larsson, Erik ;

Soderberg-Naucler, Cecilia .

CLINICAL INFECTIOUS DISEASES, 2011, 53 (10) :969-976

[62] An Analysis of Regulatory T-Cell and Th-17 Cell Dynamics during Cytomegalovirus Replication in Solid Organ Transplant Recipients [J].

Egli, Adrian ;

Silva, Moacyr, Jr. ;

O'Shea, Daire ;

Wilson, Leticia E. ;

Baluch, Aliyah ;

Lisboa, Luiz F. ;

Hidalgo, Luis G. ;

Kumar, Deepali ;

Humar, Atul .

PLOS ONE, 2012, 7 (10)

[63] Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients [J].

Egli, Adrian ;

Binet, Isabelle ;

Binggeli, Simone ;

Jaeger, Clemens ;

Dumoulin, Alexis ;

Schaub, Stefan ;

Steiger, Juerg ;

Sester, Urban ;

Sester, Martina ;

Hirsch, Hans H. .

JOURNAL OF TRANSLATIONAL MEDICINE, 2008, 6 (1)

[64] Clinical Predictors of Relapse after Treatment of Primary Gastrointestinal Cytomegalovirus Disease in Solid Organ Transplant Recipients [J].

Eid, A. J. ;

Arthurs, S. K. ;

Deziel, P. J. ;

Wilhelm, M. P. ;

Razonable, R. R. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (01) :157-161

[65] Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes [J].

Eid, Albert J. ;

Arthurs, Supha K. ;

Deziel, Paul J. ;

Wilhelm, Mark P. ;

Razonable, Raymund R. .

CLINICAL TRANSPLANTATION, 2008, 22 (02) :162-170

[66] Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study [J].

Ekberg, Henrik ;

Bernasconi, Corrado ;

Noeldeke, Jana ;

Yussim, Alexander ;

Mjoenstedt, Lars ;

Erken, Ugur ;

Ketteler, Markus ;

Navratil, Pavel .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2010, 25 (06) :2004-2010

[67] Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy [J].

Emery, VC ;

Griffiths, PD .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (14) :8039-8044

[68] Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation [J].

Emery, VC ;

Sabin, CA ;

Cope, AV ;

Gor, D ;

Hassan-Walker, AF ;

Griffiths, PD .

LANCET, 2000, 355 (9220) :2032-2036

[69] Clinical and epidemiological predictors of recurrent cytomegalovirus disease in orthotopic liver transplant recipients [J].

Falagas, ME ;

Snydman, DR ;

Griffith, J ;

Werner, BG ;

Freeman, R ;

Rohrer, R ;

Fairchild, R ;

Fawaz, K ;

Hoffman, MA ;

Kaplan, M ;

Gill, M ;

Rubin, RH ;

Dienstag, JL ;

Doran, M ;

ORourke, E ;

Vacanti, J ;

Jenkins, R ;

Lewis, WD ;

Hammer, S ;

Martin, M ;

Grady, GF ;

Leszczynski, J ;

Dougherty, N ;

Katz, A ;

Fausett, G ;

Platt, R ;

Cheeseman, SH ;

Pasternack, M ;

Gorbach, SL .

CLINICAL INFECTIOUS DISEASES, 1997, 25 (02) :314-317

[70] Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients [J].

Fayek, Sameh Adel ;

Mantipisitkul, Wana ;

Rasetto, Flavia ;

Munivenkatappa, Raghava ;

Barth, Rolf N. ;

Philosophe, Benjamin .

HPB, 2010, 12 (10) :657-663

← 2 3 4 5 6 7 8 9 10 11 →